Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Decentralized autonomous organizations are growing as alternative research funding models, but are also strong scientific communities. We should get on board.
The pangenome provides a first glimpse of the scope of human genetic diversity. But its routine adoption into research and clinical practice faces several challenges.
After over a decade of experience with immune checkpoint inhibitors in oncology, more effort needs to be spent unraveling why some patients respond — and why the majority do not — and integrating knowledge about biomarkers into patient selection in trials.